NCT07071974

A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body

Relative Bioavailability of Two BI 456906 Formulations After Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objective of this trial is to investigate relative bioavailability of BI 456906 reference formulation (Formulation A) vs. BI 456906 test formulation (Formulation B2).

Conditions

• Healthy

Interventions

Type	Name	Description
COMBINATION_PRODUCT	BI 456906 formulation A	BI 456906 formulation A
DRUG	BI 456906 formulation B2	BI 456906 formulation B2

Timeline

• Start date: 2025-07-28
• Primary completion: 2025-10-07
• Completion: 2025-10-28
• First posted: 2025-07-18
• Last updated: 2026-03-13

Locations

1 site across 1 country: Germany